Answers are grounded in this paper and cite their sources.
This discussion paper asks why nature-based solutions (NbS) struggle to attract mainstream private finance, given a biodiversity finance gap of US$722–967 billion a year. It identifies three recurring problems. Finance mechanisms vary, but all face barriers of ecological evidence, scale, risk and verification. Biodiversity measurement is fragmented, and financiers need comparable, auditable data. A governance and translation gap separates projects from investors. The paper proposes a BIOFIN Intermediary to aggregate projects, verify evidence and turn ecological performance into usable assurances for lenders. It favours flexible, interoperable measurement (for example a modular dashboard aligned with MAES and SEEA-EA) over a single metric. Drawing on Ireland’s Waters of LIFE learning site, it leaves open questions on the Intermediary’s authority, funding and accountability. It also asks how to de-risk private investment without rewarding weak ecological outcomes. It closes with nine consultation questions for practitioners, financiers and policymakers.
No takes yet. Share an insight, caveat, or question.
Reid et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: